反应详情

The title compound was prepared in a manner similar to EXAMPLE 3 using 2-chloro-5-(4-(methylsulfonyl)benzyl)-5,6,6a,7,9,10-hexahydro-[1,4]oxazino[3,4-h]pteridine (PREPARATION x9, 50 mg, 0.127 mmol), 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[3,2-b]pyridine (61.8 mg, 0.253 mmol) and PdCl2(dppf) (4.63 mg, 6.33 μmol) in dioxane (2 mL) and aqueous saturated NaHCO3 (0.4 mL). 1H NMR (400 MHz, DMSO-d6) δ 3.03-3.18 (m, 1H), 3.18-3.30 (m, 5H), 3.73-3.87 (m, 2H), 3.92-4.19 (m, 3H), 4.59-4.81 (m, 3H), 6.76-6.97 (m, 1H), 7.53-7.77 (m, 2H), 7.86-8.08 (m, 2H), 8.14-8.33 (m, 1H), 8.96-9.20 (m, 1H), 9.26-9.42 (m, 1H), 12.40-12.69 (m, 1H). ESI-MS m/z [M+H]+ calc'd for C24H24N6O3S, 477.16. found 477.2.